A Phase 1/Phase 2a Study to Evaluate the Safety, Tolerability and Efficacy of PMS-101 Administration in Patients With Burn(s)
Latest Information Update: 17 Jul 2024
At a glance
- Drugs Exosome therapies
- Indications Burns
- Focus Adverse reactions
- Sponsors Primoris Therapeutics
Most Recent Events
- 04 Jul 2024 Planned End Date changed from 30 Nov 2025 to 28 Feb 2025.
- 04 Jul 2024 Planned primary completion date changed from 30 Nov 2025 to 28 Feb 2025.
- 04 Jul 2024 Planned initiation date changed from 1 Oct 2024 to 1 Jan 2025.